CR20200452A - Compuestos de aminoacidos y métodos de uso - Google Patents
Compuestos de aminoacidos y métodos de usoInfo
- Publication number
- CR20200452A CR20200452A CR20200452A CR20200452A CR20200452A CR 20200452 A CR20200452 A CR 20200452A CR 20200452 A CR20200452 A CR 20200452A CR 20200452 A CR20200452 A CR 20200452A CR 20200452 A CR20200452 A CR 20200452A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- formula
- methods
- amino acid
- acid compounds
- Prior art date
Links
- -1 Amino acid compounds Chemical class 0.000 title 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639988P | 2018-03-07 | 2018-03-07 | |
| US201862690933P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/021243 WO2019173653A1 (en) | 2018-03-07 | 2019-03-07 | Amino acid compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200452A true CR20200452A (es) | 2020-11-19 |
Family
ID=67844341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200452A CR20200452A (es) | 2018-03-07 | 2019-03-07 | Compuestos de aminoacidos y métodos de uso |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10793564B2 (zh) |
| EP (2) | EP4328230A3 (zh) |
| JP (3) | JP6866535B2 (zh) |
| KR (1) | KR20200139676A (zh) |
| CN (1) | CN112135612A (zh) |
| AU (1) | AU2019230209B2 (zh) |
| BR (1) | BR112020018064A2 (zh) |
| CA (1) | CA3093225A1 (zh) |
| CL (1) | CL2020002290A1 (zh) |
| CO (1) | CO2020011085A2 (zh) |
| CR (1) | CR20200452A (zh) |
| CU (1) | CU24684B1 (zh) |
| DK (1) | DK3761980T3 (zh) |
| EC (1) | ECSP20063227A (zh) |
| FI (1) | FI3761980T3 (zh) |
| HR (1) | HRP20240234T1 (zh) |
| IL (2) | IL277146B2 (zh) |
| JO (1) | JOP20200212A1 (zh) |
| LT (1) | LT3761980T (zh) |
| MX (2) | MX2020009253A (zh) |
| PE (1) | PE20201502A1 (zh) |
| PH (1) | PH12020551395A1 (zh) |
| PT (1) | PT3761980T (zh) |
| RS (1) | RS65170B1 (zh) |
| SG (1) | SG11202008609UA (zh) |
| TW (1) | TW201938158A (zh) |
| WO (1) | WO2019173653A1 (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TW201835078A (zh) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| MX2020009253A (es) * | 2018-03-07 | 2021-01-15 | Pliant Therapeutics Inc | Compuestos de aminoacidos y metodos de uso. |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| EP3813818A4 (en) | 2018-06-27 | 2023-01-11 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE |
| SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体 |
| US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４β７インテグリンの阻害のための化合物 |
| CA3136745A1 (en) * | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| CN114929218A (zh) * | 2019-12-20 | 2022-08-19 | 诺华股份有限公司 | 使用整联蛋白抑制剂组合治疗肝脏疾病 |
| IL297969A (en) * | 2020-05-07 | 2023-01-01 | Pliant Therapeutics Inc | Treatment of respiratory diseases with amino acid compounds |
| CR20230262A (es) * | 2020-11-19 | 2023-07-26 | Pliant Therapeutics Inc | Inhibidor de integrina y usos de este |
| AU2022265730A1 (en) * | 2021-04-30 | 2023-11-16 | Pliant Therapeutics, Inc. | Expanded dosage regimens for integrin inhibitors |
| WO2023225119A1 (en) * | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361764B2 (en) | 1996-12-13 | 2002-03-26 | Societe L'oreal S.A. | Insoluble s-triazine derivatives and their use as UV filters |
| KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6933304B2 (en) * | 2000-06-15 | 2005-08-23 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| BR0210122A (pt) | 2001-06-01 | 2004-06-15 | Elan Pharm Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo |
| DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| BR0314180A (pt) | 2002-09-10 | 2005-08-09 | Pharmacia & Upjohn Co Llc | Aminoéteres substituìdos para o tratamento da doença de alzheimer |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
| EP2299987B1 (en) | 2008-06-06 | 2018-02-21 | Boehringer Ingelheim International GmbH | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| UA107560C2 (uk) | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| IN2015DN00099A (zh) * | 2012-07-18 | 2015-05-29 | Univ Saint Louis | |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| EP3052515A4 (en) | 2013-09-30 | 2017-03-15 | The Regents of the University of California | Anti-alphavbeta1 integrin compounds and methods |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| CA3019586A1 (en) | 2016-04-14 | 2017-10-19 | Mars, Incorporated | Compounds that modulate calcium-sensing receptor activity for modulating kokumi taste and pet food products containing the same |
| KR20190026001A (ko) * | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
| WO2018108669A1 (en) | 2016-12-12 | 2018-06-21 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| TW201835078A (zh) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
| MX2020009253A (es) * | 2018-03-07 | 2021-01-15 | Pliant Therapeutics Inc | Compuestos de aminoacidos y metodos de uso. |
| EP3813818A4 (en) | 2018-06-27 | 2023-01-11 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE |
| SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
| EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CA3136745A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| IL297969A (en) | 2020-05-07 | 2023-01-01 | Pliant Therapeutics Inc | Treatment of respiratory diseases with amino acid compounds |
-
2019
- 2019-03-07 MX MX2020009253A patent/MX2020009253A/es unknown
- 2019-03-07 RS RS20240183A patent/RS65170B1/sr unknown
- 2019-03-07 JP JP2020521559A patent/JP6866535B2/ja active Active
- 2019-03-07 CU CU2020000066A patent/CU24684B1/es unknown
- 2019-03-07 HR HRP20240234TT patent/HRP20240234T1/hr unknown
- 2019-03-07 FI FIEP19765136.7T patent/FI3761980T3/fi active
- 2019-03-07 KR KR1020207026985A patent/KR20200139676A/ko not_active Application Discontinuation
- 2019-03-07 TW TW108107688A patent/TW201938158A/zh unknown
- 2019-03-07 CR CR20200452A patent/CR20200452A/es unknown
- 2019-03-07 DK DK19765136.7T patent/DK3761980T3/da active
- 2019-03-07 US US16/296,194 patent/US10793564B2/en active Active
- 2019-03-07 CA CA3093225A patent/CA3093225A1/en active Pending
- 2019-03-07 WO PCT/US2019/021243 patent/WO2019173653A1/en active Application Filing
- 2019-03-07 EP EP23205993.1A patent/EP4328230A3/en active Pending
- 2019-03-07 SG SG11202008609UA patent/SG11202008609UA/en unknown
- 2019-03-07 IL IL277146A patent/IL277146B2/en unknown
- 2019-03-07 LT LTEPPCT/US2019/021243T patent/LT3761980T/lt unknown
- 2019-03-07 BR BR112020018064-5A patent/BR112020018064A2/pt unknown
- 2019-03-07 PE PE2020001357A patent/PE20201502A1/es unknown
- 2019-03-07 JO JOP/2020/0212A patent/JOP20200212A1/ar unknown
- 2019-03-07 AU AU2019230209A patent/AU2019230209B2/en active Active
- 2019-03-07 PT PT197651367T patent/PT3761980T/pt unknown
- 2019-03-07 IL IL305296A patent/IL305296A/en unknown
- 2019-03-07 CN CN201980030750.4A patent/CN112135612A/zh active Pending
- 2019-03-07 EP EP19765136.7A patent/EP3761980B1/en active Active
-
2020
- 2020-06-26 US US16/914,209 patent/US11560376B2/en active Active
- 2020-09-04 CL CL2020002290A patent/CL2020002290A1/es unknown
- 2020-09-04 MX MX2022014456A patent/MX2022014456A/es unknown
- 2020-09-07 CO CONC2020/0011085A patent/CO2020011085A2/es unknown
- 2020-09-07 PH PH12020551395A patent/PH12020551395A1/en unknown
- 2020-10-06 EC ECSENADI202063227A patent/ECSP20063227A/es unknown
-
2021
- 2021-04-07 JP JP2021065309A patent/JP7273882B2/ja active Active
-
2022
- 2022-12-19 US US18/084,307 patent/US20230271960A1/en active Pending
-
2023
- 2023-04-28 JP JP2023074346A patent/JP2023106425A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200452A (es) | Compuestos de aminoacidos y métodos de uso | |
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| JOP20210056A1 (ar) | مركبات حمض أميني وطرق استخدامها | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| TN2018000106A1 (en) | Farnesoid x receptor modulators | |
| MX2016004992A (es) | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk). | |
| WO2015200680A3 (en) | Prmt5 inhibitors and uses thereof | |
| MY199931A (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
| PH12018501575A1 (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
| EA201892020A1 (ru) | Индольные производные и их применение в качестве ингибиторов протеинкиназы | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| EA202092190A1 (ru) | Композиции и способы для лечения сильного запора | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| EA202190689A1 (ru) | Производные хинолина в качестве ингибиторов интегрина альфа4бета7 |